- Home
- ANIX vs MRSN Comparison
ANIX vs MRSN Comparison
Compare ANIX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | MRSN |
|---|---|---|
| Founded | 1982 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.3M | 138.8M |
| IPO Year | 1987 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ANIX | MRSN |
|---|---|---|
| Price | $3.59 | $28.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.00 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 353.5K | 86.0K |
| Earning Date | 01-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.07 | $5.21 |
| 52 Week High | $5.46 | $67.75 |
Technical Indicators
Market Signals| Indicator | ANIX | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 84.51 |
| Support Level | $4.20 | $27.31 |
| Resistance Level | $5.46 | $28.63 |
| Average True Range (ATR) | 0.42 | 0.52 |
| MACD | -0.06 | -0.54 |
| Stochastic Oscillator | 3.40 | 75.81 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.